Systematic Review

Published on 29 Sep 2023

Arthralgia adverse events due to immune-checkpoint inhibitors for lung cancer patients: a systematic review and meta-analysis

in Cancer Molecular Targets and Therapeutics

Defang Zou
Xiaoping Wang
Yamin Sun
Xi Wang
Chang Lu
Aiyun Wang
Xia Wang
Yan Yang

Frontiers in Oncology

doi 10.3389/fonc.2023.1258287

2,089 views
1 citation

Retraction

Published on 28 Sep 2023

Retraction: AnnexinA5 might suppress the phenotype of human gastric cancer cells via ERK pathway

in Cancer Molecular Targets and Therapeutics

Frontiers Editorial Office

Frontiers in Oncology

doi 10.3389/fonc.2023.1294881

1,131 views

Case Report

Published on 27 Sep 2023

Case report: The activity of multi-kinase VEGF inhibitor, Pazopanib, in metastatic undifferentiated round cell sarcomas harboring EWSR1::CREM fusion: clinicopathological series of two cases and literature review

in Cancer Molecular Targets and Therapeutics

Leticia Campoverde
Felipe Camacho
Francesco Alessandrino
Mark G. Evans
Andrew Elliot
Andrew Rosenberg
Jonathan Trent

Frontiers in Oncology

doi 10.3389/fonc.2023.1215003

2,599 views
3 citations

Original Research

Published on 25 Sep 2023

Single-cell RNA sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model

in Cancer Molecular Targets and Therapeutics

Dalton T. McLean
Jennifer J. Meudt
Loren D. Lopez Rivera
Dominic T. Schomberg
Derek M. Pavelec
Tyler T. Duellman
Darya G. Buehler
Patrick B. Schwartz
Melissa Graham
Laura M. Lee

Frontiers in Oncology

doi 10.3389/fonc.2023.1253659

4,303 views
1 citation

Systematic Review

Published on 25 Sep 2023

The efficacy and safety of different systemic combination therapies on advanced hepatocellular carcinoma: a systematic review and meta-analysis

in Cancer Molecular Targets and Therapeutics

Ping Li
Ming Hu
Mei Liu
Xiangyu Ren
Donghong Liu
Jiluo Liu
Jianhua Yin
Xiaojie Tan
Guangwen Cao

Frontiers in Oncology

doi 10.3389/fonc.2023.1197782

1,879 views
1 citation

Original Research

Published on 25 Sep 2023

Revolutionizing anti-cancer drug discovery against breast cancer and lung cancer by modification of natural genistein: an advanced computational and drug design approach

in Cancer Molecular Targets and Therapeutics

Shopnil Akash
Shabana Bibi
Partha Biswas
Nobendu Mukerjee
Dhrubo Ahmed Khan
Md. Nazmul Hasan
Nazneen Ahmeda Sultana
Md. Eram Hosen
Yousef A. Bin Jardan
Hiba-Allah Nafidi

Frontiers in Oncology

doi 10.3389/fonc.2023.1228865

4,998 views
14 citations

Original Research

Published on 22 Sep 2023

Development, quality, and influencing factors of colonoscopy in China: results from the national census in 2013 and 2020

in Cancer Molecular Targets and Therapeutics

Yun-Fei Jiao
Zhi-Yuan Cheng
Ye Gao
Chu-Ting Yu
Hui-Shan Jiang
Ting-Lu Wang
Ying Deng
Han Lin
Tian-Jiao Wang
Wei Wang

Frontiers in Oncology

doi 10.3389/fonc.2023.1276520

2,341 views
3 citations

Case Report

Published on 19 Sep 2023

The novel EGFR mutations (p.E746_S752delinsI, p.T751_I759delinsG, p.L747_S752delinsAA) in patients with non-small cell lung cancer and the clinical treatment strategy: three case reports

in Cancer Molecular Targets and Therapeutics

Yamin Meng
Xiaodong Li
Lei Zhang
Minhua Ye

Frontiers in Oncology

doi 10.3389/fonc.2023.1129629

2,517 views
1 citation

Mini Review

Published on 15 Sep 2023

Beyond liver cancer, more application scenarios for alpha-fetoprotein in clinical practice

in Cancer Molecular Targets and Therapeutics

Chenyu Ma
Yuexinzi Jin
Yuhan Wang
Huaguo Xu
Jiexin Zhang

Frontiers in Oncology

doi 10.3389/fonc.2023.1231420

1,779 views
1 citation

Original Research

Published on 14 Sep 2023

LTe2 induces cell apoptosis in multiple myeloma by suppressing AKT phosphorylation at Thr308 and Ser473

in Cancer Molecular Targets and Therapeutics

Yuanjiao Zhang
Jiacheng Qian
Mingmei Jiang
Shu Yang
Lianxin Zhou
Qin Zhang
Liping Lin
Ye Yang

Frontiers in Oncology

doi 10.3389/fonc.2023.1269670

1,413 views

Hypothesis and Theory

Published on 14 Sep 2023

Opioids and immune checkpoint inhibitors differentially regulate a common immune network in triple-negative breast cancer

in Cancer Molecular Targets and Therapeutics

Joseph R. Scarpa
Giacomo Montagna
George Plitas
Amitabh Gulati
Gregory W. Fischer
Joshua S. Mincer

Frontiers in Oncology

doi 10.3389/fonc.2023.1267532

1,895 views
1 citation

Original Research

Published on 13 Sep 2023

System analysis based on the lysosome-related genes identifies HPS4 as a novel therapy target for liver hepatocellular carcinoma

in Cancer Molecular Targets and Therapeutics

Ke‐Jie He
Zhiqiang Nie

Frontiers in Oncology

doi 10.3389/fonc.2023.1221498

1,593 views
1 citation

Review

Published on 12 Sep 2023

Cellular senescence: a double-edged sword in cancer therapy

in Cancer Molecular Targets and Therapeutics

Shuai Xiao
Dongmin Qin
Xueyang Hou
Lingli Tian
Yeping Yu
Rui Zhang
Hao Lyu
Dong Guo
Xing-Zhen Chen
Cefan Zhou

Frontiers in Oncology

doi 10.3389/fonc.2023.1189015

10,516 views
20 citations

Review

Published on 08 Sep 2023

Single domain Camelid antibody fragments for molecular imaging and therapy of cancer

in Cancer Molecular Targets and Therapeutics

Shulin Li
Sanne Johanna Maria Hoefnagel
Kausilia Krishnawatie Krishnadath

Frontiers in Oncology

doi 10.3389/fonc.2023.1257175

3,416 views
2 citations

Original Research

Published on 08 Sep 2023

Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma

in Cancer Molecular Targets and Therapeutics

Kristina Breitenecker
Viola Hedrich
Franziska Pupp
Doris Chen
Eva Řezníčková
Gregor Ortmayr
Heidemarie Huber
Gerhard Weber
Lorenz Balcar
Matthias Pinter

Frontiers in Oncology

doi 10.3389/fonc.2023.1238883

2,710 views
2 citations

Original Research

Published on 07 Sep 2023

CAR requires Gadd45β to promote phenobarbital-induced mouse liver tumors in early stage

in Cancer Molecular Targets and Therapeutics

Takeshi Hori
Kosuke Yokobori
Rick Moore
Masahiko Negishi
Tatsuya Sueyoshi

Frontiers in Oncology

doi 10.3389/fonc.2023.1217847

1,619 views
2 citations

Navigation group

Articles

Arthralgia adverse events due to immune-checkpoint inhibitors for lung cancer patients: a systematic review and meta-analysis

Retraction: AnnexinA5 might suppress the phenotype of human gastric cancer cells via ERK pathway

Case report: The activity of multi-kinase VEGF inhibitor, Pazopanib, in metastatic undifferentiated round cell sarcomas harboring EWSR1::CREM fusion: clinicopathological series of two cases and literature review

Single-cell RNA sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model

The efficacy and safety of different systemic combination therapies on advanced hepatocellular carcinoma: a systematic review and meta-analysis

Revolutionizing anti-cancer drug discovery against breast cancer and lung cancer by modification of natural genistein: an advanced computational and drug design approach

Development, quality, and influencing factors of colonoscopy in China: results from the national census in 2013 and 2020

The novel EGFR mutations (p.E746_S752delinsI, p.T751_I759delinsG, p.L747_S752delinsAA) in patients with non-small cell lung cancer and the clinical treatment strategy: three case reports

Beyond liver cancer, more application scenarios for alpha-fetoprotein in clinical practice

LTe2 induces cell apoptosis in multiple myeloma by suppressing AKT phosphorylation at Thr308 and Ser473

Opioids and immune checkpoint inhibitors differentially regulate a common immune network in triple-negative breast cancer

System analysis based on the lysosome-related genes identifies HPS4 as a novel therapy target for liver hepatocellular carcinoma

Cellular senescence: a double-edged sword in cancer therapy

Single domain Camelid antibody fragments for molecular imaging and therapy of cancer

Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma

CAR requires Gadd45β to promote phenobarbital-induced mouse liver tumors in early stage